Survival Effect of Supportive Care Services for Turkish Patients with Metastatic Gastric Cancer

  • Namal, Esat (Department of Medical Oncology, Florence Nightingale Hospital) ;
  • Ercetin, Candas (Department of General Surgery, Bagcilar Training and Research Hospital) ;
  • Tokocin, Merve (Department of General Surgery, Bagcilar Training and Research Hospital) ;
  • Akcali, Zafer (Department of Medical Oncology, Ufuk University, Dr. Ridvan Ege Hospital) ;
  • Yigitbas, Hakan (Department of General Surgery, Bagcilar Training and Research Hospital) ;
  • Yavuz, Erkan (Department of General Surgery, Bagcilar Training and Research Hospital) ;
  • Celebi, Fatih (Department of General Surgery, Bagcilar Training and Research Hospital) ;
  • Totoz, Tolga (Department of Anesthesiology, Bagcilar Training and Research Hospital) ;
  • Pamukcu, Ozgul (Department of Internal Medicine, Sisli Etfal Training and Research Hospital) ;
  • Saglam, Emel (Department of Internal Medicine, Bagcilar Training and Research Hospital)
  • Published : 2015.03.04


Background: Gastric cancer is the second most common cause of cancer- related deaths worldwide and ranks $11^{th}$ or $14^{th}$ among all deaths. Patients with advanced disease require supportive care along with the medical and/or surgical treatment. Aim: To assess the need for palliative care for patients with advanced tumours along with standard clinical therapy. Materials and Methods: Eighty-four patients with metastatic (stage 4) gastric cancer, including both patients who had received surgical treatment or not, were followed up in Bagcilar Training and Research Hospital, Division of Medical Oncology between 2011 and 2014. They were categorised as supportive care (-) (Group 1, n=37) and (+) groups (Group 2, n=47) and evaluated retrospectively. Results: Demographic characteristics of the patients were as follows: mean age, Group 1, $65.2{\pm}10.5$ years, Group $2,63.7{\pm}11.3$ years; male/female ratio, Group 1, 21/16, Group 2, 28/19; distribution of Eastern Cooperative Oncology Group (ECOG) performance scores of 0 and 1, Group 1, ECOG 0 (n=9) and 1 (n=14), Group 2, ECOG 0 (34) and 1 (n=13) (p<0.0001); patients receiving second-line, Group 1 (n=7) and Group 2 (n=22) (p<0.008) or third - line chemotherapy,Group 2 (n=6) (p<0.02); mortality rates, Group 1, (n=28; 75.6%) and Group 2 (n=30; 63.8%); progression-free survival (PFS) rates, Group 1, $17.4{\pm}6$ weeks, Group 2, $28.3{\pm}16.2$ weeks; statistically significant overall survival rates, Group 1, $20.8{\pm}8.2$ weeks and Group 2, $28.3{\pm}162$ weeks (p<0.01). Conclusions: The supportive care team (medical oncologist, general surgeon, internal medicine specialist, algologist, psychiatrist and radiologist) can play a role in the treatment of metastatic gastric tumours, with improvements shown in terms of the performance status of cases, eligibility of patients to be on chemotherapy programmes for longer duration and overall survival rates in Turkey.


  1. Alfano CM, Rowland JH (2006). Recovery issues in cancer survivorship: a new challenge for supportive care. Cancer J, 12, 432-43.
  2. Andreyev HJN, Norman AR, Oates J, Cunningham D (1998). Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer, 34, 503-9.
  3. Bang YJ, Van Cutsem E, Feyereislova A, et al (2010). ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97.
  4. Bilici A (2014). Treatment options in patients with metastatic gastric cancer: Current status and future perspectives. World J Gastroenterol, 20, 3905-15.
  5. Berrino F, Capocaccia R, Esteve J, et al (1999). Survival of cancer patients in europe: the eurocare-2 study. international agency for research on cancer 1999.
  6. Birkmeyer JD, Siewers AE, Finlayson EV, et al (2002). Hospital volume and surgical mortality in the United States. New England J Med, 346, 1128-37.
  7. Birkmeyer JD, Stukel TA, Siewers AE, et al (2003). Surgeon volume and operative mortality in the United States. N Engl J Med, 349, 2117-27.
  8. Cheng H, Sit JW, Chan CW, et al (2013). Social support and quality of life among Chinese breast cancer survivors: Findings from a mixed methods study. Eur J Oncol Nurs, 17, 788-96.
  9. Cunningham D, Hole D, Taggart DJ, et al (1987). Evaluation of the prognostic factors in gastric cancer: the effect of chemotherapy on survival. Br J Surg, 74, 715-20.
  10. Enzinger PC, Mayer RJ (2003). Esophageal cancer. New England J Med, 349, 2241-52.
  11. Al-Batran SE, Hartmann JT, Probst S, et al (2008). Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol, 26, 1435-42.
  12. Greenlee RT, Murray T, Bolden S, Wingo PA (2000). Cancer statistics, 2000. CA Cancer J Clin, 50, 7-33.
  13. Hsu CH, Yeh KH, Chen LT, et al (1997). Weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancer: an effective and low-toxic regimen for patients with poor general condition. Oncology, 54, 275-80.
  14. Hwang JE, Kim HN, Kim DE, et al (2011). Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer, 11, 489.
  15. Janunger KG, Halfstrom L, Nygen P, Glimelius B (2001). A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol, 40, 309-26.
  16. Jeung HC, Rha SY, Shin SJ, et al (2007). A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Br J Cancer, 97, 458-63.
  17. Kang Y, Ohtsu A, Van Cutsem E, et al (2010). AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). Proc ASCO, 28, 4007.
  18. Lavin PT, Bruckner HW, Plaxe SC (1982). Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer, 50, 2016-23.<2016::AID-CNCR2820501007>3.0.CO;2-2
  19. Liu J, Huang XE, Feng JF (2014). Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC). Asian Pac J Cancer Prev, 15, 6587-90.
  20. Maehara Y, Sugimachi K, Ogawa M, et al (1993). Influence of preoperative performance status on survival time of patients with advanced gastric cancer following noncurative resection. Anticancer Res, 13, 201-4.
  21. Park SA, Chung SH, Shin EH (2012). Attitudes of nurses toward supportive care for advanced cancer Patients. Asian Pac J Cancer Prev, 13, 4953-8.
  22. Pasini F, Fraccon AP, Manzoni G (2011). The role of chemotherapy in metastatic gastric cancer. Anticancer research, 31, 3543-54.
  23. Rosenbaum E, Gautier H, Fobair P, et al (2004). Cancer supportive care, improving the quality of life for cancer patients. A program evaluation report. Support Care Cancer, 12, 293-301.
  24. Shin HR, Jung KW, Won YJ, Park JG (2004). 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat, 36, 103-14.
  25. Faghani S, Rahmani A, Parizad N, et al (2014). Social support and its predictors among Iranian cancer survivors. Asian Pac J Cancer Prev, 15, 9767-71.
  26. Glimelius B, Ekstrom K, Hoffman K, et al (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol, 8, 163-8.
  27. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.
  28. Solano JP, Gomes B, Higginson IJ ( 2006). A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage, 31, 58-69.
  29. Tomasello G, Liguigli W, Poli R, et al (2014). Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial. Gastric Cancer, 17, 711-7.
  30. Trumper M, Ross PJ, Cunningham D, et al (2006). Efficacy and tolerability in elderly patients with advanced oesophagogastric cancer: a pooled analysis of three clinical trials. Eur J Cancer, 42, 827-34.
  31. Ugur O, Elcigil A, Arslan D, Sonmez A (2014). Responsibilities and difficulties of caregivers of cancer patients in home care. Asian Pac J Cancer Prev, 15, 725-9.
  32. Walling AM, Asch SM, Lorenz KA, et al (2012). The quality of supportive care among inpatients dying with advanced cancer. Support Care Cancer, 20, 2189-94.
  33. Wagner AD, Unverzagt S, Grothe W, et al (2010). Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev, 3, 4064.
  34. Wilson D, Hiller L, Geh JI (2005). Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol, 17, 81-90.
  35. Wilson D, Hiller L, Geh JI (2005). Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol, 17, 81-90.
  36. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al (2006). V325 study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol, 24, 4991-7.
  37. Viklund P, Lindblad M, Lagergren J (2005). Influence of surgeryrelated factors on quality of life after esophageal or cardia cancer resection. World J Surg, 29, 841-8.
  38. Viklund P, Lindblad M, Lu M, et al (2006). Risk factors for complications after esophageal cancer resection: a prospective population-based study in Sweden. Ann Surgery, 243, 204-11.
  39. Viklunda P, Wengstro Y, Lagergrena J (2006). Supportive care for patients with oesophageal and other upper gastrointestinal cancers: The role of a specialist nurse in the team. European J Oncol Nurs, 10, 353-63.
  40. Xu CD (2014). Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage gastric cancer. Asian Pac J Cancer Prev, 15, 10273-6.